MOTS-c and Relationships: What Has—and Has Not—Been Studied

A Better Question Than “Will It Improve My Relationship?”

MOTS-c is a mitochondria-derived peptide first studied for metabolic signaling. Claims that it produces more energy, better mood, greater libido, or easier social connection often chain several assumptions together: an injected product changes metabolism; that change improves subjective energy; energy changes behavior; and the behavioral change improves a relationship.

Each link needs evidence. The relationship claim needs all of them.

FDA’s July 2026 scientific evaluation states:

“The nomination did not include, and FDA has not identified, any clinical studies or human exposure data for MOTS-c via any route of administration.”

The issuer is the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research. This 24-word excerpt is a denominator, not a verdict that harm is proven. It means administered-human benefit, safety, dose, and relationship claims cannot be inferred from the reviewed record (FDA, Evaluation of MOTS-c-Related Bulk Drug Substances, PDF page 28).

The Outcome-Provenance Map

The empty right-hand column is the important result. A metabolic mechanism is not a validated relationship intervention.

What the Human Studies Actually Measured

One controlled exercise study measured endogenous mitochondrial-derived peptides before and after exercise. Its authors reported that plasma peptide levels were not correlated with fitness outcomes, a useful warning against turning a biomarker change into a performance promise (PMID 34351816). This study did not inject MOTS-c and did not measure relationship quality.

A separate study in healthy men found that circulating MOTS-c decreased across age groups while skeletal-muscle expression moved in the opposite direction. That tissue-versus-plasma divergence makes a simple “low level equals deficiency” story untenable (PMID 32182209; PMCID PMC7138593). It also did not administer the peptide or test mood, libido, or relationships.

The exercise evidence audit maps this distinction in more detail. Exercise can influence endogenous MOTS-c without proving that an injected product reproduces exercise or improves a person’s social life.

What the Mouse Study Can—and Cannot—Carry

In mice, intermittent MOTS-c treatment improved physical capacity across young, middle-age, and old groups. The same paper reported that exercise induced endogenous MOTS-c expression in humans (PMID 33473109; DOI 10.1038/s41467-020-20790-0). Those are two different experiments: treatment in mice and observation in humans.

The paper does not establish that human injections improve energy, fatigue, mood, sexual function, or relationships. “Exercise biology is interesting” and “this peptide will improve intimacy” are separated by multiple untested causal steps.

The Registered Trial Does Not Yet Close the Gap

ClinicalTrials.gov lists NCT07505745, a recruiting Phase 2a randomized trial with an estimated 120 adults who have prediabetes and overweight or obesity. Its listed outcomes include insulin sensitivity, adverse events, HbA1c, fasting glucose, two-hour glucose, and antidrug antibodies. The record reports no results and does not list mood, libido, fatigue, or relationship quality as outcomes (ClinicalTrials.gov, NCT07505745).

Even a positive metabolic result would not automatically answer a relationship question. It would show what the trial measured in its selected population, over its specified time—not every downstream life effect people hope for.

How to Interpret a Personal Story

A person may sincerely feel more energetic or connected after starting a product. That observation still sits alongside several competing explanations:

• training, sleep, diet, alcohol use, or stress changed at the same time;
• expectation and attention altered how symptoms were noticed;
• another medicine or supplement changed;
• the compounded product’s identity, concentration, or impurities were not independently established;
• natural variation or relationship events occurred during the same period.

An anecdote can generate a research question. It cannot supply the missing control group, product verification, or validated outcome measure.

A More Useful Relationship-Specific Decision

If low energy, low libido, depressed mood, pain, sleep disruption, or medication adverse effects are affecting a relationship, the useful next step is to identify that problem directly. Those symptoms have different causes and evidence-based evaluation paths. A product marketed as a broad mitochondrial solution can delay the more specific question.

The young-adult safety evidence map explains why age does not create an administered-human safety denominator. The rare-but-serious risk review separates known evidence gaps from harms that have actually been observed.

Medical review of this revision is pending. FDA, trial sponsors, investigators, authors, institutions, and quoted authorities do not endorse MOTS-c, HealthRX.com, or this page.